- DANCE- “A Phase IIb Randomized, Parallel Group, Double-Blind, PlaceboControlled, Repeat Dose, Multi-Site Study Investigating the Safety, Tolerability, and Efficacy of Personalized Phage Treatment and Standard of Care Antimicrobials for Patients with Diabetic Foot Osteomyelitis due to S. aureus”- Adaptive Phage Therapeutics NOW ENROLLING
- PTK0796-NTM-2020 3 -A phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc)- Paratek Pharmaceuticals, Inc ENROLLMENT COMPLETED
- ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)- Insmed NOW ENROLLING
-
EBO-301-“A Phase 2/3, Randomized, Double-blind, Placebo-controlled,
Multicenter, Prospective Study to Assess the Efficacy, Safety, and
Pharmacokinetics of Orally Administered Epetraborole in Patients with
Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)”-
AN2 Therapeutics, Inc ENROLLMENT COMPLETE
- ICoN-1- A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of
the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) When Added to Guideline- Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension (Part B) NOW ENROLLING - MRXC-302-A Phase 3, Multicenter, Randomized, Double-Blind Study to
Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections NOW ENROLLING - IDCTC is actively adding more studies. Please check back soon to inquire about study opportunities please email [email protected]